The market has been down on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.
Intellia Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NTLA!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With NTLA Stock Today?
Intellia Therapeutics Inc (NTLA) stock is trading at $25.99 as of 10:00 AM on Tuesday, Nov 14, an increase of $2.18, or 9.16% from the previous closing price of $23.81. The stock has traded between $25.29 and $26.69 so far today. Volume today is low. So far 314,526 shares have traded compared to average volume of 1,408,490 shares.
To see InvestorsObserver's Sentiment Score for Intellia Therapeutics Inc click here.
More About Intellia Therapeutics Inc
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Click Here to get the full Stock Report for Intellia Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
